奥马珠单抗靶向治疗慢性鼻窦炎伴鼻息肉的研究进展

doi:10.6040/j.issn.1673-3770.0.2023.250

摘要/Abstract

摘要： 慢性鼻窦炎伴鼻息肉(chronic rhinosinusitis with nasal polyps, CRSwNP)是一种常见的慢性炎症性疾病,其病因学复杂,发病机制尚不完全清楚。部分患者临床表现顽固,经功能性鼻内镜手术和最大限度的鼻用糖皮质激素规范治疗后仍难以控制症状,奥马珠单抗作为一种新型的重组人源化抗免疫球蛋白E(immunoglobulin E, IgE)抗体,在CRSwNP的靶向治疗中发挥着重要的作用。近年来,奥马珠单抗在成人顽固性CRSwNP中疗效显著,其通过阻断2型炎症中关键细胞因子IgE的信号传导达到治疗作用。本文就CRSwNP的免疫机制、治疗现状及奥马珠单抗的作用机制、临床疗效、不良反应进行综述。

关键词: 慢性鼻窦炎伴鼻息肉, 奥马珠单抗, 免疫球蛋白E, 靶向治疗

Abstract: Chronic rhinosinusitis with nasal polyps(CRSwNP)is a common chronic inflammatory disease with a complex etiology and incompletely understood pathogenesis. Some patients show persistent clinical manifestations, and it remains difficult to control symptoms after functional nasal endoscopic surgery and standardized treatment with high doses of nasal corticosteroids. Omalizumab is a novel recombinant humanized anti-IgE antibody that plays a crucial role in the targeted therapy of CRSwNP. Recent studies have demonstrated that omalizumab can effectively treat refractory CRSwNP in adults by blocking the signaling of the key cytokine IgE in type 2 inflammation. This article reviews the immune mechanism, treatment status, mechanism of action, clinical efficacy, and adverse reactions of omalizumab in the treatment of CRSwNP.

Key words: Chronic sinusitis with nasal polyps, Omalizumab, Immunoglobulin E, Targeted therapy

中图分类号:

R765.4

张韵秋,任秀敏,徐鸥,董金辉,王建星. 奥马珠单抗靶向治疗慢性鼻窦炎伴鼻息肉的研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(1): 136-140.

ZHANG Yunqiu, REN Xiumin, XU Ou, DONG Jinhui, WANG Jianxing. Research progress on omalizumab targeted therapy for chronic sinusitis with nasal polyps[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(1): 136-140.

参考文献

[1] Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020[J]. Rhinology, 2020, 58(Suppl S29): 1-464. doi:10.4193/Rhin20.600
[2] Chen S, Zhou AN, Emmanuel B, et al. Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis[J]. Curr Med Res Opin, 2020, 36(11): 1897-1911. doi:10.1080/03007995.2020.1815682
[3] Armengot-Carceller M, Gómez-Gómez MJ, García-Navalón C, et al. Effects of omalizumab treatment in patients with recalcitrant nasal polyposis and mild asthma: a multicenter retrospective study[J]. Am J Rhinol Allergy, 2021, 35(4): 516-524. doi:10.1177/1945892420972326
[4] Vogt F, Sahota J, Bidder T, et al. Chronic rhinosinusitis with and without nasal polyps and asthma: Omalizumab improves residual anxiety but not depression[J]. Clin Transl Allergy, 2021, 11(1): e12002. doi:10.1002/clt2.12002
[5] Naclerio R, Baroody F, Bachert C, et al. Clinical research needs for the management of chronic rhinosinusitis with nasal polyps in the new era of biologics: a national institute of allergy and infectious diseases workshop[J]. J Allergy Clin Immunol Pract, 2020, 8(5): 1532-1549.e1. doi:10.1016/j.jaip.2020.02.023
[6] Damask CC, Ryan MW, Casale TB, et al. Targeted molecular therapies in allergy and rhinology[J]. Otolaryngol Head Neck Surg, 2021, 164(1_suppl): S1-S21. doi:10.1177/0194599820965233
[7] 石帅, 郑泉. 度普利尤单抗在慢性鼻窦炎伴鼻息肉治疗中的研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 36-42. doi:10.6040/j.issn.1673-3770.0.2021.565 SHI Shuai, ZHENG Quan. Research advances of dupilumab in the treatment of chronic rhinosinusitis with nasal polyps[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 36-42. doi:10.6040/j.issn.1673-3770.0.2021.565
[8] Kim DW, Cho SH. Emerging endotypes of chronic rhinosinusitis and its application to precision medicine[J]. Allergy Asthma Immunol Res, 2017, 9(4): 299-306. doi:10.4168/aair.2017.9.4.299
[9] Zheng M, Sima YT, Liu CY, et al. Clinical effectiveness and potential predictability of omalizumab in patients with difficult-to-treat chronic rhinosinusitis with nasal polyps and asthma based on the noninvasive markers- A real-life prospective study[J]. World Allergy Organ J, 2022, 15(10): 100702. doi:10.1016/j.waojou.2022.100702
[10] Kariyawasam HH, James LK. Chronic rhinosinusitis with nasal polyps: targeting IgE with anti-IgE omalizumab therapy[J]. Drug Des Devel Ther, 2020, 14: 5483-5494. doi:10.2147/DDDT.S226575
[11] Kohanski MA, Workman AD, Patel NN, et al. Solitary chemosensory cells are a primary epithelial source of IL-25 in patients with chronic rhinosinusitis with nasal polyps[J]. J Allergy Clin Immunol, 2018, 142(2): 460-469.e7. doi:10.1016/j.jaci.2018.03.019
[12] Bachert C, Nan Z, Cavaliere C, et al. Biologics for chronic rhinosinusitis with nasal polyps[J]. J Allergy Clin Immunol, 2020, 145(3): 725-739. doi:10.1016/j.jaci.2020.01.020
[13] Patel GB, Kern RC, Bernstein JA, et al. Current and future treatments of rhinitis and sinusitis[J]. J Allergy Clin Immunol Pract, 2020, 8(5): 1522-1531. doi:10.1016/j.jaip.2020.01.031
[14] Thomas WW 3rd, Harvey RJ, Rudmik L, et al. Distribution of topical agents to the paranasal sinuses: an evidence-based review with recommendations[J]. Int Forum Allergy Rhinol, 2013, 3(9): 691-703. doi:10.1002/alr.21172
[15] Harvey RJ, Snidvongs K, Kalish LH, et al. Corticosteroid nasal irrigations are more effective than simple sprays in a randomized double-blinded placebo-controlled trial for chronic rhinosinusitis after sinus surgery[J]. Int Forum Allergy Rhinol, 2018, 8(4): 461-470. doi:10.1002/alr.22093
[16] 中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组, 中华医学会耳鼻咽喉头颈外科学分会鼻科学组. 中国慢性鼻窦炎诊断和治疗指南(2018)[J]. 中华耳鼻咽喉头颈外科杂志, 2019, 54(2): 81-100. doi: 10.3760/cma.j.issn.1673-0860.2019.02.001
[17] Patel GB, Kudlaty EA, Guo A, et al. Impact of type 2 targeting biologics on acute exacerbations of chronic rhinosinusitis[J]. Allergy Asthma Proc, 2021, 42(5): 417-424. doi:10.2500/aap.2021.42.210058
[18] Calus L, van Bruaene N, Bosteels C, et al. Twelve-year follow-up study after endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyposis[J]. Clin Transl Allergy, 2019, 9: 30. doi:10.1186/s13601-019-0269-4
[19] Tai JH, Lee K, Kim TH. Current perspective on nasal delivery systems for chronic rhinosinusitis[J]. Pharmaceutics, 2021, 13(2): 246. doi:10.3390/pharmaceutics13020246
[20] Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials[J]. J Allergy Clin Immunol, 2016, 137(6): 1742-1750.e4. doi:10.1016/j.jaci.2015.12.1342
[21] 陈玉迪, 胡艳, 隋海晶, 等. 抗IgE单克隆抗体在变态反应性疾病治疗中的应用[J]. 中华临床免疫和变态反应杂志, 2018, 12(3): 302-307. doi:10.3969/j.issn.1673-8705.2018.03.008 CHEN Yudi, HU Yan, SUI Haijing, et al. Use of anti-IgE monoclonal antibody in treatment of allergic diseases[J]. Chinese Journal of Allergy and Clinical Immunology, 2018, 12(3): 302-307. doi:10.3969/j.issn.1673-8705.2018.03.008
[22] Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials[J]. J Allergy Clin Immunol, 2020, 146(3): 595-605. doi:10.1016/j.jaci.2020.05.032
[23] Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children[J]. Cochrane Database Syst Rev, 2014(1): CD003559. doi:10.1002/14651858.CD003559
[24] 张宇, 高迎霞, 顾宁琰, 等. 奥马珠单抗对慢性自发性荨麻疹患者的临床疗效和安全性分析[J]. 中华皮肤科杂志, 2021, 54(7): 582-585. doi:10.35541/cjd.20201261 ZHANG Yu, GAO Yingxia, GU Ningyan, et al. Clinical efficacy and safety of omalizumab in the treatment of chronic spontaneous urticaria[J]. Chinese Journal of Dermatology, 2021, 54(7): 582-585. doi:10.35541/cjd.20201261
[25] Passalacqua G, Ciprandi G, Canonica GW. United airways disease: therapeutic aspects[J]. Thorax, 2000, 55(2): 26-27. doi:10.1136/thorax.55.suppl_2.s26
[26] 刘蕊, 石磊, 翟钊. 奥马珠单抗治疗过敏性鼻炎伴哮喘的疗效分析[J]. 中国处方药, 2021, 19(4): 79-80. doi:10.3969/j.issn.1671-945X.2021.04.039
[27] Massanari M, Nelson H, Casale T, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma[J]. J Allergy Clin Immunol, 2010, 125(2): 383-389. doi:10.1016/j.jaci.2009.11.022
[28] Gevaert P, Calus L, van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma[J]. J Allergy Clin Immunol, 2013, 131(1): 110-116.e1. doi:10.1016/j.jaci.2012.07.047
[29] Pinto JM, Mehta N, DiTineo M, et al. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis[J]. Rhinology, 2010, 48(3): 318-324. doi:10.4193/Rhino09.144
[30] 申珅, 娄鸿飞, 闫冰, 等. 抗IgE单克隆抗体治疗合并哮喘的复发性慢性鼻窦炎伴鼻息肉的短期疗效研究[J]. 中华耳鼻咽喉头颈外科杂志, 2021, 56(10): 1035-1041. doi: 10.3760/cma.j.cn115330-20210608-00338 SHEN Shen, LOU Hongfei, YAN Bing, et al. Short-term efficacy of anti-IgE monoclonal antibody in patients with recurrent chronic rhinosinusitis with nasal polyps combined with asthma[J]. Chinese Journal of Otorhinolaryngology Head and Neck Surgery, 2021, 56(10): 1035-1041. doi: 10.3760/cma.j.cn115330-20210608-00338
[31] Gevaert P, Saenz R, Corren J, et al. Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study[J]. J Allergy Clin Immunol, 2022, 149(3): 957-965.e3. doi:10.1016/j.jaci.2021.07.045
[32] Lieberman PL, Jones I, Rajwanshi R, et al. Anaphylaxis associated with omalizumab administration: risk factors and patient characteristics[J]. J Allergy Clin Immunol, 2017, 140(6): 1734-1736.e4. doi:10.1016/j.jaci.2017.07.013
[33] Corren J, Casale TB, Lanier B, et al. Safety and tolerability of omalizumab[J]. Clin Exp Allergy, 2009, 39(6): 788-797. doi:10.1111/j.1365-2222.2009.03214.x

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed